PhaseBio Pharmaceuticals, Inc. News Releases https://investors.phasebio.com/ PhaseBio Pharmaceuticals, Inc. News Releases en PhaseBio Announces Positive Preliminary Results from Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor in Older and Elderly Subjects https://investors.phasebio.com/news-releases/news-release-details/phasebio-announces-positive-preliminary-results-phase-2a Top-Line Data Are Consistent with Previously Published Phase 1 Trial MALVERN, Pa. and SAN DIEGO , June 17, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for Mon, 17 Jun 2019 16:01:00 -0400 PhaseBio Pharmaceuticals, Inc. News Releases 7151 PhaseBio Reports First Quarter 2019 Financial Results and Recent Corporate Progress https://investors.phasebio.com/news-releases/news-release-details/phasebio-reports-first-quarter-2019-financial-results-and-recent Completed underwritten public offering of common stock that raised $46.2 million in net proceeds Received FDA Breakthrough Therapy designation for PB2452 Results from Phase 1 clinical trial of PB2452 published in the New England Journal of Medicine and presented at the American College of Thu, 09 May 2019 16:01:00 -0400 PhaseBio Pharmaceuticals, Inc. News Releases 7076 PhaseBio To Report First Quarter 2019 Financial Results and Recent Corporate Progress on May 9, 2019 https://investors.phasebio.com/news-releases/news-release-details/phasebio-report-first-quarter-2019-financial-results-and-recent MALVERN, Pa. and SAN DIEGO , May 02, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced it will report financial and business Thu, 02 May 2019 08:00:00 -0400 PhaseBio Pharmaceuticals, Inc. News Releases 7071 PhaseBio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares https://investors.phasebio.com/news-releases/news-release-details/phasebio-announces-closing-public-offering-common-stock-and-full MALVERN, Pa. and SAN DIEGO , April 16, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced the closing of its underwritten public Tue, 16 Apr 2019 16:01:00 -0400 PhaseBio Pharmaceuticals, Inc. News Releases 7061 PhaseBio Announces Pricing of Public Offering of Common Stock https://investors.phasebio.com/news-releases/news-release-details/phasebio-announces-pricing-public-offering-common-stock MALVERN, Pa. , and SAN DIEGO , April 11, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced the pricing of its underwritten public Thu, 11 Apr 2019 21:19:00 -0400 PhaseBio Pharmaceuticals, Inc. News Releases 7046 PhaseBio Announces Proposed Public Offering of Common Stock https://investors.phasebio.com/news-releases/news-release-details/phasebio-announces-proposed-public-offering-common-stock MALVERN, Pa. and SAN DIEGO , April 09, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that it has commenced an underwritten Tue, 09 Apr 2019 16:45:00 -0400 PhaseBio Pharmaceuticals, Inc. News Releases 7021 PhaseBio Announces Global License of PB1023 for the Treatment of Sarcopenia-Related Diseases to ImmunoForge https://investors.phasebio.com/news-releases/news-release-details/phasebio-announces-global-license-pb1023-treatment-sarcopenia Expands use of PhaseBio ELP biopolymer platform designed to support more convenient dosing of proteins and peptides   MALVERN, Pa. and SAN DIEGO , April 09, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc.  (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development Tue, 09 Apr 2019 08:00:00 -0400 PhaseBio Pharmaceuticals, Inc. News Releases 7011 PhaseBio Receives FDA Breakthrough Therapy Designation for PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor https://investors.phasebio.com/news-releases/news-release-details/phasebio-receives-fda-breakthrough-therapy-designation-pb2452 In Phase 1 clinical trial, PB2452 provided immediate and sustained reversal of ticagrelor antiplatelet effects MALVERN, Pa. and SAN DIEGO , April 08, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and Mon, 08 Apr 2019 16:01:00 -0400 PhaseBio Pharmaceuticals, Inc. News Releases 6996 PhaseBio Reports Fourth Quarter and Full-Year 2018 Financial and Business Results https://investors.phasebio.com/news-releases/news-release-details/phasebio-reports-fourth-quarter-and-full-year-2018-financial-and Results from Phase 1 clinical trial of PB2452 published in the New England Journal of Medicine and presented at the American College of Cardiology’s Annual Scientific Session Initiated Phase 2b trial of PB1046 for the treatment of pulmonary arterial hypertension Closed initial public offering that Tue, 26 Mar 2019 16:01:00 -0400 PhaseBio Pharmaceuticals, Inc. News Releases 6966 PhaseBio Announces Term Loan of up to $15 Million https://investors.phasebio.com/news-releases/news-release-details/phasebio-announces-term-loan-15-million Entered into term loan facility with Silicon Valley Bank and WestRiver Innovation Lending Fund to borrow up to $15 million Funds will be used to advance clinical development of PB2452, a reversal agent for ticagrelor, and for repayment of the existing term loan MALVERN, Pa. Mon, 25 Mar 2019 16:30:00 -0400 PhaseBio Pharmaceuticals, Inc. News Releases 6951